Sugi Predict

Sugi Predict / Compounds / SCHEMBL5342209

SCHEMBL5342209

SCHEMBL5342209

CC(C)(C)OC(=O)CNC1CCNCC1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 4/20 0.40
▸ DPP7 Q9UHL4 1/20 0.40
▸ POLB P06746 1/20 0.37
▸ GNAI3 P08754 3/20 0.37
▸ GNAO1 P09471 3/20 0.37
▸ GNAI1 P63096 3/20 0.37
▸ SSTR1 P30872 1/20 0.35
▸ SSTR4 P31391 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KCNH2 Q12809 1/20 0.34
▸ ABCB1 P08183 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ FAP Q12884 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ DPP9 Q86TI2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3297927 0.90 KCNH2 (0.47) EPHX1DPP7POLBSSTR1SSTR4
SCHEMBL6346898 0.90 KCNH2 (0.47) EPHX1DPP7POLBSSTR1SSTR4
SCHEMBL7380787 0.88 EPHX1 (0.38) EPHX1L3MBTL1ABCB1HRH3
SCHEMBL11366947 0.84 BTK (0.45) EPHX1DPP7POLBL3MBTL1HRH3
SCHEMBL7277999 0.84 EPHX1 (0.46) EPHX1DPP7POLBHRH3DPP4
SCHEMBL11373425 0.83 EPHX1 (0.49) EPHX1DPP7POLBDPP4FAP
SCHEMBL785469 0.83 L3MBTL1 (0.36) EPHX1L3MBTL1ABCB1HRH3
SCHEMBL2547400 0.83 EPHX1 (0.49) EPHX1DPP7POLBDPP4FAP
SCHEMBL17284631 0.82 EPHX1 (0.45) EPHX1DPP7POLBGNAI3GNAO1
SCHEMBL8585956 0.82 NR1H2 (0.42) EPHX1L3MBTL1ABCB1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117157285-A Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors 阿尔麦克探索有限公司 2023-12-01 — — CN disclosed
EP-3189038-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2022-11-23 — — EP disclosed
US-10864202-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-12-15 — — US disclosed
US-20200108052-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-09 — — US disclosed
US-10543198-B2 Inhibitor of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-01-28 — — US disclosed
CN-108727341-A A kind of pyrroles's substituted indole ketones derivant or its pharmaceutically acceptable salt and their preparation method and purposes 上海先行医药开发有限公司 2018-11-02 — — CN disclosed
US-20180028508-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2018-02-01 — — US disclosed
US-9822119-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-21 — — US disclosed
EP-3189038-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2017-07-12 — — EP disclosed
US-20160108046-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. 2016-04-21 — — US disclosed
CN-1282243-A Pharmaceutical composition containing anilide derivative for antagonizing CCR5 TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-01-31 — — CN disclosed
CN-1223659-A Fused imidazopyridine derivatives as antihyperlipidemic agents TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-07-21 — — CN disclosed
US-5741792-A ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-04-21 — — US disclosed
US-5741799-A ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-04-21 — — US disclosed
US-5583146-A Heterocyclic thrombin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 — — US disclosed
US-5420283-A Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide PFIZER INC. (US) 1995-05-30 — — US disclosed
EP-0644892-A1 INHIBITORS OF ANGIOTENSIN I CHYMASE(S) INCLUDING HUMAN HEART CHYMASE PFIZER INC. (US) 1995-03-29 — — EP disclosed
WO-1995004043-A1 OPTICAL RESOLUTION OF GAMMA-(4-(((1,1-DIMETHYLETHOXY)CARBONYL)METHYLAMINO)-PIPERIDINYL-1)-GAMMA-OXO-ALPHA-(PHENYLMETHYL)-BUTYNIC ACID WITH (N,S-)CYCLOHEXYL ETHYLAMINE PFIZER INC. (US) 1995-02-09 — — WO disclosed
EP-0601459-A2 Sulfonamido heterocyclic thrombin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1994-06-15 — — EP disclosed
WO-1993025574-A1 INHIBITORS OF ANGIOTENSIN I CHYMASE(S) INCLUDING HUMAN HEART CHYMASE PFIZER INC. (US) 1993-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200108052-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A EPHX1 945/4885DPP7 1059/4885POLB 2723/4885
US-10864202-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A EPHX1 945/4885DPP7 1059/4885POLB 2723/4885
US-20180028508-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A EPHX1 945/4885DPP7 1059/4885POLB 2723/4885
US-20160108046-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A EPHX1 945/4885DPP7 1059/4885POLB 2723/4885
US-10543198-B2 Inhibitor of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A EPHX1 968/4885DPP7 1150/4885POLB 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.